Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I

Inclusion Criteria: * Patients, male or female, \> 18 years of age, * Patients who are scheduled for an elective PCI with a drug eluting stent * Patients willing to return for all required follow up visits. * Patients live/work within a 60 mile radius of the Washington Hospital Center. Exclusion Criteria: * Patient has experienced an acute myocardial infarction within the preceding 48 hours of the subsequent angioplasty. * Unprotected left main coronary disease with \>50% stenosis; * Patients with renal failure requiring dialysis; * Patients with a documented ejection fraction \< 30 percent at the time of subsequent PCI; * Patient with a life expectancy less than 12 months or malignancy. * Known allergies to aspirin or clopidogrel bisulfate (PlavixR) and that cannot be medically managed; * Planned surgery or other indication for requiring the cessation of clopidogrel within 12 months of PCI; * Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study. * Patients with known history of bleeding diathesis; * Prothrombin time \>1.5 times control; coumadin therapy * Platelet count \<100 000/mm3; * Hematocrit \<25%; * Creatinine \>4.0 mg/dL; * Thienopyridine use within 5 days of enrollment * Glycoprotein (GP) IIb/IIIa use within 8 hours of enrollment or any indication were the operator will require GP IIb/IIIa inhibitor use during the hospitalization.